Nicotiana benthamiana as a potential source for producing anti-dengue virus D54 neutralizing therapeutic antibody
Issued Date
2024-06-01
Resource Type
eISSN
2215017X
Scopus ID
2-s2.0-85194559232
Journal Title
Biotechnology Reports
Volume
42
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biotechnology Reports Vol.42 (2024)
Suggested Citation
Krittanai S., Rattanapisit K., Bulaon C.J.I., Pitaksajjakul P., Keadsanti S., Ramasoota P., Strasser R., Phoolcharoen W. Nicotiana benthamiana as a potential source for producing anti-dengue virus D54 neutralizing therapeutic antibody. Biotechnology Reports Vol.42 (2024). doi:10.1016/j.btre.2024.e00844 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/98629
Title
Nicotiana benthamiana as a potential source for producing anti-dengue virus D54 neutralizing therapeutic antibody
Corresponding Author(s)
Other Contributor(s)
Abstract
Dengue virus (DENV), transmitted by mosquitoes, is classified into four serotypes (DENV1-4) and typically causes mild, self-limiting symptoms upon initial infection. However, secondary infection can lead to severe symptoms due to antibody-dependent enhancement (ADE). To address this, anti-DENV antibodies are being developed with the goal of neutralizing infection without ADE activity. Previous attempts using a 54_hG1 antibody from CHO-K1 mammalian cells resulted in ADE induction, increasing viral infection. This study aimed to express the D54 monoclonal antibody in Nicotiana benthamiana. The plant-produced antibody had a similar neutralizing profile to the previous 54_hG1 antibody. Notably, the ADE activities of the plant-derived antibody were successfully eliminated, with no sign of viral induction. These findings suggest that N. benthamiana could be a source of therapeutic DENV antibodies. The method offers several advantages, including lower ADE, cost-effectiveness, simple facility requirements, scalability, and potential industrial-scale production in GMP facilities.